Vitrectomy Clinical Trials

Clinical trials related to Vitrectomy Procedure

Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Neovascular Age-related Macular Degeneration (AMD) That Shows no Response to Existing Therapy

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this clinical trial is to assess safety and efficacy in patients with Neovascular Age-related Macular Degeneration with no response to existing therapy. The main measures it aims to answer are: * Investigation of adverse events * Changes in clinical testing data * Changes in vital signs * Changes in intraocular pressure of the therapeutic eye * Changes in testing of anterior segment of the therapeutic eye Participants will be implanted one sheet of PAL-222 into the subretinal space through pars plana vitrectomy. Researchers will compare pre and post implantation of therapeutic eye to see if any safety issues recognized

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:

• Patients aged between 18 and 85 years at the time of consent acquisition

• Patients diagnosed neovascular AMD in one or both eyes

• Patients with corrected letter vision in the subject eye of 20 letters or more (equivalent to decimal vision of 0.05) and less than 70 letters (equivalent to decimal vision of 0.5)

• Patients who apply to one or more of the followings:

• ① RPE defect site in the RPE tear includes the Fovea

• ② The Macular atrophy confirmed by low fundus autofluorescence extends to the fovea

• ③ Patients with choroidal thinning (200 micrometer and less), and subretinal fluid resistant to standard treatment

• ④ Patients with cystoid macular degeneration with photoreceptor cell loss and intraretinal fluid above fibrovascular pigment epithelial detachment

• Patients who had little improvement in exudative changes, with persistent exudative changes to date, and no improvement, or deterioration of vision in two treatments with VEGF inhibitor therapy (two consecutive administration at intervals of 11 weeks +/- 3 days or less within the past year), after existing therapy

Locations
Other Locations
Japan
Hyogo Prefectural Amagasaki General Medical Center
RECRUITING
Amagasaki
Nagoya City University Hospital
RECRUITING
Nagoya
Yamaguchi University Hospital
RECRUITING
Ube
Contact Information
Primary
Hitoshi Kusano, M.D.
clinicaltrial@pharmabio.co.jp
+81 44-742-9980
Time Frame
Start Date: 2024-09-12
Estimated Completion Date: 2029-08
Participants
Target number of participants: 10
Treatments
Experimental: Therapeuitic group
One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy.
Sponsors
Leads: PharmaBio Corporation

This content was sourced from clinicaltrials.gov